Home – PTX Therapeutics2019-06-11T22:44:30+00:00

Novel cancer therapies targeting key cancer pathways

READ MORE
Prescient Therapeutics PTX

We are a clinical stage oncology company developing novel drugs
that show great promise as potential new therapies to treat a range of cancers.

BROKER REPORT

The broker reports included on this page of the website have not been commissioned or endorsed by Prescient Therapeutics Limited (Prescient) or its officers and are provided for information purposes only.  The information contained in these report is not produced by Prescient and is not intended to be investment or financial product advice given by Prescient.  Prescient recommends recipients of the reports make their own assessment of Prescient before making any investment decision. Any inquiries with respect to the reports should be directed to the relevant issuer of the report.

CLICK LINK TO VIEW BROKER REPORT

prescient therapeutics

OUR COMPANY

Prescient Therapeutics’ novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.

Digital Brochure

Two Page Fact Sheet

prescient therapeutics

OUR SCIENCE

Our technologies emanate from renowned institutions Yale University and the Moffitt Cancer Center and are backed by a myriad of peer review publications.

prescient therapeutics

LATEST NEWS

18/11/2019PTX in new CAR-T collaborationPDF
14/11/20191st patient dosed in trial for first in class drug PTX-100PDF
08/11/2019Receipt of R&D Tax RebatePDF
31/10/2019Prescient Ausbio Ras PresentationPDF
30/10/2019September 2019 Appendix 4C - QuarterlyPDF
16/10/2019Notice of Annual General Meeting/Proxy FormPDF
26/08/2019Appendix 4E and 2019 Annual ReportPDF